Onko Pharmaceuticals has first taken its place in pharmaceutical sector in 1987 by introducing blood derivative products in Turkey, and by getting distribution on exclusive base from the best known pharmaceutical companies of Europe. Until now Onko keeps on serving in this field by still being the leading importer of blood products through satisfying the high need of blood products in Turkey on a large scale.
In 1995, Kocsel Pharmaceuticals has joined to the family with hepatitis B vaccine and biological product group. In subsequent years, it has undertaken the mission of providing a part of Turkeys vaccine needs, which has occurred due to the attendance of Turkey to the global immunization program. After one year, as a result of success in its own sector; Onko & Kocsel Pharmaceuticals, has achieved to extend its horizon in the pharmaceutical sector by setting up an oncology business unit.
In 2002, Onko & Kocsel Pharmaceuticals took the first step on manufacturing by taking over manufacturing licenses from Roche Pharmaceuticals. This brought a new vision to Onko & Kocsel Pharmaceuticals.
Onko & Kocsel Pharmaceuticals has achieved to reflect its fast success also to its organizational structure and adapted Total Quality System to mantain professional management.
Onko & Kocsel Pharmaceuticals focused on adding new products to its mainly Oncology, Radiation Oncology, Hematology, Neurology, Infection diseases, Urology, Physical Medicine & Rehabilitation, Orthopedics, Rheumatology, Immunology, Dermatology and Internal Medicine portfolio year after year. With its dedicated staff and well organized and positioned structure Onko & Kocsel Pharmaceuticals has reached its target consumers throughout Turkey. In the medical marketing; strong professional customer-focused relations, effective meeting organizations, effective communication skills, power of investment and clinically-focused scientific approaches have constituted its vision. Onko & Kocsel Pharmaceuticals plays a significant role with well-educated, professionally trained, experienced, dynamic and result oriented sale force.
Onko & Kocsel keeps showing promising rise by signing new business agreements with strong companies and expanding its product portfolio in the light of innovative and stable development. Onko & Kocsel Pharmaceuticals looks ahead with confidence with an experience more than 20 years in the Pharmaceutical market.
Contact Details Onko ilaç San. ve Tic. A.Ş.
Koşuyolu Cad. No:34 34718 Koşuyolu Kadıköy – İstanbul / Türkiye
Tuğçe Koç describes the company’s initial aspirations in targeting the higher value-added therapeutic area of oncology and the type of market opportunities that are present domestically and internationally. With over…
After an international career spanning 25 years, Demet Russ returned to her native Turkey to lead the Janssen affiliate during a tumultuous time and is aiming to give back to…
Avinash Potnis of Novartis Turkey discusses potential solutions to the country’s access and pricing dilemma which has raised concerns of system sustainability. Potnis also highlights the strengths of Turkey’s healthcare…
Ingrid Drechsel, head of Bayer’s pharma operations in Turkey and Iran, discusses the complexity of managing two countries under economic pressure and the advantages of Bayer’s longstanding relationship in both…
Menarini’s general manager for Turkey, the Middle East and Africa Uğur Bingöl discusses the Italian company’s restructuring in the region and its desire to replicate its success in Turkey across…
The secretary general for Turkey’s Pharmaceutical Manufacturers Association (IEIS), Savaş Malkoç, highlights their objective of increasing R&D expenditure and Turkey’s big opportunity ahead in biosimilars production. In addition, Malkoç discusses…
Janssen’s Managing Director for Turkey, Demet Russ, discusses her return to the country after 25 years abroad, having worked for Johnson & Johnson in different local, regional and global roles…
As one of the leading pharma companies in Turkey, DEVA is pioneering a new approach to generics in the country. Chairman of the Board and CEO Philipp Haas discusses the…
As COVID-19 began spreading through the world, the race to understand the disease by scientists and doctors took off. After just a few months, it became apparent that people with…
The president of the Turkish Society of Cardiology, Mustafa Kemal Erol, discusses the prevalence of cardiovascular disease, which accounts for over a third of deaths in Turkey, the improvements made…
AmCham Turkey’s executive director, Asli Özelli, examines the impact of US companies on the Turkish economy with over USD 50 billion in investment, their help during the pandemic, the chamber’s…
Dr Burak Cem, Novo Nordisk Vice President and General Manager for Turkey, outlines the company’s big bet on Turkey as a future regional hub through deep investment in clinical trials,…
Turkey’s former Minister of Health, Bülent Akarcali, outlines the country’s healthcare system evolution over the past decades, comparing the improvements to the difference between a Ford Model T to a…